Effect of polymorphisms of NF-κB and PXR on platinum-based chemotherapy for non-small cell lung cancer.
10.11817/j.issn.1672-7347.2016.03.002
- Author:
Yaxing ZHOU
1
,
2
,
3
;
Pei YANG
4
;
Yingzhi LIU
1
,
2
,
3
;
Liansheng WANG
1
,
2
,
3
Author Information
1. Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008
2. Institute of Clinical Pharmacology
3. Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
4. Affiliated Hunan Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410014, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Carcinoma, Non-Small-Cell Lung;
Genotype;
Humans;
Lung Neoplasms;
NF-kappa B;
Platinum;
Polymorphism, Genetic;
Pregnane X Receptor;
Receptors, Steroid;
Transcription Factor RelA
- From:
Journal of Central South University(Medical Sciences)
2016;41(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of polymorphisms of NF-κB rs230521, NF-κB rs4648068 and pregnane X receptor (PXR) rs3814058 on platinum-based chemotherapy for non-small cell lung cancer patients.
METHODS:We collected 262 cases of non-small cell lung cancer patients, and then analyzed the genotypes of NF-κB and PXR by MassARRAY method. The impact of polymorphisms on efficacy, gastrointestinal toxicity and hematological toxicity was analyzed by logistic regression.
RESULTS:Compared to patients with GG genotype, patients with NF-κB rs230521 CC genotype had the higher risk to suffer hematological toxicity (OR=3.485, P=0.011). Patients with PXR rs3814058 CC and CT genotype exhibited higher possibility to suffer hematological toxicity than those with TT (OR=2.045, P=0.048). Polymorphism of NF-κB rs4648068 did not show significant effect on chemotherapy efficacy and occurrence of gastrointestinal toxicity and hematological toxicity.
CONCLUSION:Patients with NF-κB rs230521 CC, PXR rs3814058 CC and CT had higher risk to suffer hematological toxicity during platinum-based chemotherapy for non-small cell lung cancer. A rational dosage and course of treatment should be chosen to protect the patients with high risk genotype suffering hematological toxicity during their platinum-based therapy.
